About Us :

Speciality

The Oncology Institute Francisco Gentil (Instituto Português de Oncologia Francisco Gentil) is renowned for providing comprehensive cancer care and advanced oncological services. Here are some of the specialized services offered:

1. Medical Oncology:

   • Diagnosis, treatment, and management of solid tumors and hematological cancers.
   • Chemotherapy, immunotherapy, targeted therapy, and hormone therapy.

2. Radiation Oncology:

   • Advanced radiation therapy techniques including external beam radiation therapy (EBRT), brachytherapy, and stereotactic radiosurgery (SRS).
   • Intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT).

3. Surgical Oncology:

   • Specialized surgical procedures for various types of cancers including minimally invasive and robotic-assisted surgeries.
   • Complex surgical resections and reconstructions.

4. Pediatric Oncology:

   • Comprehensive care for children with cancer including chemotherapy, radiation therapy, and surgical interventions.
   • Multidisciplinary approach involving pediatric oncologists, surgeons, and support staff.

5. Hematology:

   • Treatment of blood cancers such as leukemia, lymphoma, and myeloma.
   • Bone marrow and stem cell transplantation services.

6. Palliative Care:

   • Symptom management and supportive care for patients with advanced cancer.
   • Psychological support and pain management.

Quality

The Portuguese Oncology Institute Francisco Gentil (IPO), encompassing branches in Lisbon, Porto, and Coimbra, is highly regarded for its comprehensive cancer care, research, and education.

Quality and Recognition

1. Clinical Excellence: IPO Lisboa is a leading institution in the south of Portugal, recognized for its extensive research and high standards in cancer treatment. It has a substantial number of active clinical trials and non-interventional studies, indicating a robust engagement in advancing oncology research. The institute is well-staffed with 360 physicians and 571 nurses, ensuring a high level of care for patients​​.

2. Research and Innovation: IPO Porto is noted for its dedicated Early Phase Clinical Trials Unit, established in 2019, which focuses on promoting patient access to innovative treatments through clinical research. The unit specializes in early drug development and biomarker-driven clinical trials, enhancing the institution's role in cutting-edge cancer therapy​.

3. Accreditations and Certifications: IPO Porto is accredited by the Organization of European Cancer Institutes (OECI) as a Comprehensive Cancer Center. This accreditation underscores its commitment to high standards in cancer care and research​​.

Facilities and Services

1. Specialized Departments: Both IPO Lisboa and IPO Porto have specialized departments catering to various types of cancer, including pediatric oncology, esophageal cancer, testicular cancer, sarcomas, and more. These specialized units are equipped with state-of-the-art technology and facilities​​.

Vision & Mission

Vision

The Oncology Institute Francisco Gentil aims to be a leader in cancer care and research, offering world-class treatment and support services to patients while advancing the understanding and treatment of cancer through cutting-edge research and innovation.

Mission

The mission of the Oncology Institute Francisco Gentil is to provide comprehensive, patient-centered care to individuals affected by cancer. This includes prevention, diagnosis, treatment, and palliative care, all delivered with a commitment to excellence, compassion, and collaboration.

Strategic Objectives

1. Enhance Patient Care: Continuously improve the quality of care provided to patients through the adoption of the latest technologies and treatment protocols.
2. Promote Research and Innovation: Foster a culture of research and innovation to advance the understanding and treatment of cancer, ensuring the institute remains at the forefront of oncological advancements.
3. Strengthen Education and Training: Provide ongoing education and training opportunities for healthcare professionals to ensure they are equipped with the latest knowledge and skills in cancer care.
4. Expand Access to Care: Increase access to cancer care services across the region, ensuring that all patients have timely and equitable access to high-quality treatment and support.
5. Foster Collaboration: Build and maintain partnerships with other healthcare institutions, research organizations, and community groups to enhance the institute's ability to provide comprehensive care and support.
6. Promote Public Awareness and Prevention: Lead initiatives aimed at raising public awareness about cancer prevention and early detection, encouraging healthy lifestyles and regular screenings.

Awards & Recognition

The Oncology Institute Francisco Gentil, also known as the Portuguese Oncology Institute (IPO), has achieved significant recognition for its contributions to cancer care and research. Here are some key awards and recognitions:

1. ESMO Designated Centre of Integrated Oncology and Palliative Care: IPO is accredited by the European Society for Medical Oncology (ESMO) for its comprehensive cancer care and palliative services, highlighting its commitment to integrated patient care​.

2. OECI Accreditation: The IPO Porto branch is accredited by the Organization of European Cancer Institutes (OECI) as a Comprehensive Cancer Center. This prestigious accreditation acknowledges the institute’s excellence in cancer treatment, research, and education​ ​.

3. CHKS Certification: IPO Porto is certified by the CHKS (Caspe Healthcare Knowledge Systems) for its high standards in healthcare quality and patient safety. This certification underscores the institute's dedication to maintaining superior clinical and operational practices​.

4. ISO 9001:2008 Certification: The institute holds the ISO 9001:2008 certification, which attests to its effective quality management systems and its continuous improvement in providing cancer care services​.

5. Excellent Rating by FCT: The Research Center at IPO Porto (CI-IPOP) received an "Excellent" rating from the Portuguese Science Foundation (FCT) in its latest international evaluation. This recognition reflects the center's outstanding research activities and contributions to oncology​​.

These accolades demonstrate the institute's dedication to providing high-quality cancer care, advancing oncology research, and integrating palliative care to support patients comprehensively.